| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 27(3); 1995 > Article
Journal of the Korean Cancer Association 1995;27(3): 383-389.
진행성 위암에서 5-Fluorouracil 과 Cisplatin ( FP ) 복합 화학요법의 효과
김금정, 김정희, 김시영, 윤휘중, 조경삼
5-Fluorouracil and Cisplatin ( FP ) Combination Chemotherapy in Advanced Gastric Cancer
Keum Jung Kim, Jeong Hee Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho
Thirty-one patients with advanced gastric cancer were entered into the trial between May 1988 to June l993. The patients recieved 5-fluorouracil 1,000 mg/m by l2-hour continuous infusions for 5 consecutive days, cisplatin 100 mg/m IV on day 1 and repeated every three weeks. The results were as following: 1) Among the 31 treated patients, 27 patients had measurable disease and were evaluable for response. The overall response rate was 18.5%. The median duration of response was 6 months. 2) The estimated median survival time was 7.5 months for all 31 patients. The median survival was 8.6 months in responder, and 6.4 months in non-responder. There was no significar.t difference between the two group. 3) Nausea and vomiting of WHO grades 2 and 3 were observed in 48.7%. Alopecia was observed in all patients, but most of patients were WHO grade l or 2. WHO grades 1 and 2 neurotoxicities and diarrhea occurred in 22.6%, 7.8% of patients. WHO grades 2 and 3 neutrope- nia were observed in 2.6% of patients and WHO grade 1 thrombocytopenia was observed in 9.6 of patients, but there were no toxic deaths and no bleeding complications from thrombocytopenia. In conclusion, although this PP regimen showed similar toxicity profiles than the other regimen, response rate and survival benefit were not observed.
Key words: FP chemotherapy, Advanced gastric cancer
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI